Stavudine-induced macrocytosis during therapy for human immunodeficiency virus infection

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 459-460

  Martin, Gregory J ^a   Blazes, David L ^a   Mayers, Douglas L ^a   Spooner, Katherine M ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROCYTIC ANEMIA; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; PRIORITY JOURNAL;

EID: 0032787913     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520245     Document Type: Article

References (3)

1. 1. Richman DD, Fischl MA, Gricco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-7.
2. 2. Gelmon K, Montaner JS, Fanning M, et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989;3:555-61.
3. 3. Browne MJ, Mayer KH, Chafee SB, et al. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase 1 trial. J Infect Dis 1993;167:21-9.